Barclays PLC Purchases 7,267 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Barclays PLC lifted its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 11.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 71,896 shares of the company’s stock after purchasing an additional 7,267 shares during the quarter. Barclays PLC owned about 0.10% of Kiniksa Pharmaceuticals worth $1,423,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its position in shares of Kiniksa Pharmaceuticals by 2.0% in the 4th quarter. Geode Capital Management LLC now owns 492,630 shares of the company’s stock worth $9,744,000 after buying an additional 9,654 shares during the period. JPMorgan Chase & Co. grew its holdings in Kiniksa Pharmaceuticals by 138.9% in the fourth quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company’s stock worth $9,451,000 after purchasing an additional 277,827 shares during the period. Peregrine Capital Management LLC increased its stake in shares of Kiniksa Pharmaceuticals by 1.8% during the fourth quarter. Peregrine Capital Management LLC now owns 244,043 shares of the company’s stock valued at $4,827,000 after purchasing an additional 4,361 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at approximately $3,955,000. Finally, Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Kiniksa Pharmaceuticals by 1.9% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 199,525 shares of the company’s stock valued at $3,947,000 after purchasing an additional 3,673 shares during the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Ross Moat sold 18,259 shares of the company’s stock in a transaction on Monday, April 21st. The stock was sold at an average price of $20.29, for a total transaction of $370,475.11. Following the completion of the sale, the insider now owns 9,415 shares in the company, valued at approximately $191,030.35. This represents a 65.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Mark Ragosa sold 8,879 shares of the stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $23.10, for a total value of $205,104.90. Following the completion of the transaction, the chief financial officer now directly owns 23,382 shares in the company, valued at approximately $540,124.20. This represents a 27.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 218,548 shares of company stock valued at $5,210,745 over the last three months. Insiders own 54.57% of the company’s stock.

Wall Street Analysts Forecast Growth

KNSA has been the subject of a number of analyst reports. Wedbush reaffirmed an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Jefferies Financial Group raised their price target on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday, April 29th. Finally, Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They issued a “buy” rating and a $40.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $38.80.

Kiniksa Pharmaceuticals Trading Down 0.3 %

Kiniksa Pharmaceuticals stock opened at $27.65 on Friday. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $17.38 and a 12 month high of $28.15. The stock has a fifty day simple moving average of $21.77 and a two-hundred day simple moving average of $21.32. The firm has a market cap of $2.01 billion, a price-to-earnings ratio of -197.49 and a beta of 0.31.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.02 by $0.09. The company had revenue of $137.79 million during the quarter, compared to the consensus estimate of $128.35 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. Kiniksa Pharmaceuticals’s revenue for the quarter was up 72.5% on a year-over-year basis. During the same period last year, the company earned ($0.25) EPS. On average, equities research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.